A citation-based method for searching scientific literature

Jyotsana Pandey, Akhilesh K Tamrakar. Expert Opin Ther Pat 2019
Times Cited: 7







List of co-cited articles
20 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Physiology of renal glucose handling via SGLT1, SGLT2 and GLUT2.
Chiara Ghezzi, Donald D F Loo, Ernest M Wright. Diabetologia 2018
71
42

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
42

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
42

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
42

Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials.
Vlado Perkovic, Dick de Zeeuw, Kenneth W Mahaffey, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Terrance D Barrett, Michele Weidner-Wells, Hsiaowei Deng, David R Matthews,[...]. Lancet Diabetes Endocrinol 2018
208
28

Synthesis and biological evaluation of 6-hydroxyl C-aryl glucoside derivatives as novel sodium glucose co-transporter 2 (SGLT2) inhibitors.
Xiaoyu Zhao, Bin Sun, Hongbo Zheng, Jun Liu, Lilin Qian, Xiaoning Wang, Hongxiang Lou. Bioorg Med Chem Lett 2018
6
33

Discovery of tofogliflozin, a novel C-arylglucoside with an O-spiroketal ring system, as a highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.
Yoshihito Ohtake, Tsutomu Sato, Takamitsu Kobayashi, Masahiro Nishimoto, Naoki Taka, Koji Takano, Keisuke Yamamoto, Masayuki Ohmori, Marina Yamaguchi, Kyoko Takami,[...]. J Med Chem 2012
84
28

An update on the safety of SGLT2 inhibitors.
André J Scheen. Expert Opin Drug Saf 2019
47
28


Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis.
Despoina Vasilakou, Thomas Karagiannis, Eleni Athanasiadou, Maria Mainou, Aris Liakos, Eleni Bekiari, Maria Sarigianni, David R Matthews, Apostolos Tsapas. Ann Intern Med 2013
500
28

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
B M Brenner, M E Cooper, D de Zeeuw, W F Keane, W E Mitch, H H Parving, G Remuzzi, S M Snapinn, Z Zhang, S Shahinfar. N Engl J Med 2001
28

SGLT2 Protein Expression Is Increased in Human Diabetic Nephropathy: SGLT2 PROTEIN INHIBITION DECREASES RENAL LIPID ACCUMULATION, INFLAMMATION, AND THE DEVELOPMENT OF NEPHROPATHY IN DIABETIC MICE.
Xiaoxin X Wang, Jonathan Levi, Yuhuan Luo, Komuraiah Myakala, Michal Herman-Edelstein, Liru Qiu, Dong Wang, Yingqiong Peng, Almut Grenz, Scott Lucia,[...]. J Biol Chem 2017
116
28

Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus.
David Z I Cherney, Bruce A Perkins, Nima Soleymanlou, Maria Maione, Vesta Lai, Alana Lee, Nora M Fagan, Hans J Woerle, Odd Erik Johansen, Uli C Broedl,[...]. Circulation 2014
678
28

Evaluation of Glomerular Hemodynamic Function by Empagliflozin in Diabetic Mice Using In Vivo Imaging.
Kengo Kidokoro, David Z I Cherney, Andrea Bozovic, Hajime Nagasu, Minoru Satoh, Eiichiro Kanda, Tamaki Sasaki, Naoki Kashihara. Circulation 2019
73
28

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
Vlado Perkovic, Meg J Jardine, Bruce Neal, Severine Bompoint, Hiddo J L Heerspink, David M Charytan, Robert Edwards, Rajiv Agarwal, George Bakris, Scott Bull,[...]. N Engl J Med 2019
28


Biology of human sodium glucose transporters.
Ernest M Wright, Donald D F Loo, Bruce A Hirayama. Physiol Rev 2011
669
28

SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Thomas A Zelniker, Stephen D Wiviott, Itamar Raz, Kyungah Im, Erica L Goodrich, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Remo H M Furtado,[...]. Lancet 2019
856
28

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
Christoph Wanner, Silvio E Inzucchi, John M Lachin, David Fitchett, Maximilian von Eynatten, Michaela Mattheus, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Bernard Zinman. N Engl J Med 2016
28

Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion.
Caroline Bonner, Julie Kerr-Conte, Valéry Gmyr, Gurvan Queniat, Ericka Moerman, Julien Thévenet, Cédric Beaucamps, Nathalie Delalleau, Iuliana Popescu, Willy J Malaisse,[...]. Nat Med 2015
369
28


Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor tofogliflozin.
Motoshi Ouchi, Kenzo Oba, Kohei Kaku, Hideki Suganami, Akihiro Yoshida, Yasunori Fukunaka, Promsuk Jutabha, Asuka Morita, Naoyuki Otani, Keitaro Hayashi,[...]. Diabetes Obes Metab 2018
10
14

C-Glucosides with heteroaryl thiophene as novel sodium-dependent glucose cotransporter 2 inhibitors.
Yuichi Koga, Shigeki Sakamaki, Mitsuya Hongu, Eiji Kawanishi, Toshiaki Sakamoto, Yasuo Yamamoto, Hirotaka Kimata, Keiko Nakayama, Chiaki Kuriyama, Yasuaki Matsushita,[...]. Bioorg Med Chem 2013
11
14



HbA1c and Hypoglycemia Reductions at 24 and 52 Weeks With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: The European inTandem2 Study.
Thomas Danne, Bertrand Cariou, Phillip Banks, Michael Brandle, Helmut Brath, Edward Franek, Jake A Kushner, Pablo Lapuerta, Darren K McGuire, Anne L Peters,[...]. Diabetes Care 2018
76
14

Development of sotagliflozin, a dual sodium-dependent glucose transporter 1/2 inhibitor.
Pablo Lapuerta, Brian Zambrowicz, Paul Strumph, Arthur Sands. Diab Vasc Dis Res 2015
64
14

Sodium-glucose cotransporter 2 inhibitors and inflammation in chronic kidney disease: Possible molecular pathways.
Habib Yaribeygi, Alexandra E Butler, Stephen L Atkin, Niki Katsiki, Amirhossein Sahebkar. J Cell Physiol 2018
33
14

Development of a Scalable Synthesis of Tofogliflozin.
Yoshihito Ohtake, Takashi Emura, Masahiro Nishimoto, Koji Takano, Keisuke Yamamoto, Satoshi Tsuchiya, Sang-Yong Yeu, Yasushi Kito, Nobuaki Kimura, Sunao Takeda,[...]. J Org Chem 2016
5
20


Efficacy and safety of empagliflozin in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials.
R Devi, Ghanshyam Mali, Indrani Chakraborty, Mazhuvancherry Kesavan Unnikrishnan, Suhaj Abdulsalim. Postgrad Med 2017
14
14

Dapagliflozin slows the progression of the renal and liver fibrosis associated with type 2 diabetes.
Li Tang, Yuanyuan Wu, Mi Tian, C David Sjöström, Ulrika Johansson, Xiao-Rong Peng, David M Smith, Yufeng Huang. Am J Physiol Endocrinol Metab 2017
42
14



Ertugliflozin: First Global Approval.
Anthony Markham. Drugs 2018
17
14

Canagliflozin, a novel SGLT2 inhibitor for treatment of type 2 diabetes.
Stefanie C Nigro, Daniel M Riche, Michelle Pheng, William L Baker. Ann Pharmacother 2013
18
14

Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study.
John B Buse, Satish K Garg, Julio Rosenstock, Timothy S Bailey, Phillip Banks, Bruce W Bode, Thomas Danne, Jake A Kushner, Wendy S Lane, Pablo Lapuerta,[...]. Diabetes Care 2018
92
14

Discovery of a clinical candidate from the structurally unique dioxa-bicyclo[3.2.1]octane class of sodium-dependent glucose cotransporter 2 inhibitors.
Vincent Mascitti, Tristan S Maurer, Ralph P Robinson, Jianwei Bian, Carine M Boustany-Kari, Thomas Brandt, Benjamin M Collman, Amit S Kalgutkar, Michelle K Klenotic, Michael T Leininger,[...]. J Med Chem 2011
59
14

Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin.
J Bolinder, Ö Ljunggren, L Johansson, J Wilding, A M Langkilde, C D Sjöström, J Sugg, S Parikh. Diabetes Obes Metab 2014
270
14

C-Aryl glucoside SGLT2 inhibitors containing a biphenyl motif as potential anti-diabetic agents.
Yuyang Ding, Liufeng Mao, Dengfeng Xu, Hui Xie, Ling Yang, Hongjiang Xu, Wenjun Geng, Yong Gao, Chunguang Xia, Xiquan Zhang,[...]. Bioorg Med Chem Lett 2015
8
14

Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives.
Chiara Maria Assunta Cefalo, Francesca Cinti, Simona Moffa, Flavia Impronta, Gian Pio Sorice, Teresa Mezza, Alfredo Pontecorvi, Andrea Giaccari. Cardiovasc Diabetol 2019
34
14

Luseogliflozin for the treatment of type 2 diabetes.
Yutaka Seino. Expert Opin Pharmacother 2014
16
14

Luseogliflozin: first global approval.
Anthony Markham, Shelley Elkinson. Drugs 2014
47
14

SGLT2 inhibitors in the pipeline for the treatment of diabetes mellitus in Japan.
Hiroyuki Ito, Masahiro Shinozaki, Shinya Nishio, Mariko Abe. Expert Opin Pharmacother 2016
12
14

Synthesis and α-glucosidase inhibition activity of dihydroxy pyrrolidines.
Sivaprasad Kasturi, Sujatha Surarapu, Srinivas Uppalanchi, Jaya Shree Anireddy, Shubham Dwivedi, Hasitha Shilpa Anantaraju, Yogeeswari Perumal, Dilep Kumar Sigalapalli, Bathini Nagendra Babu, Krishna S Ethiraj. Bioorg Med Chem Lett 2017
19
14

Effects of a new SGLT2 inhibitor, luseogliflozin, on diabetic nephropathy in T2DN rats.
Naoki Kojima, Jan M Williams, Teisuke Takahashi, Noriyuki Miyata, Richard J Roman. J Pharmacol Exp Ther 2013
95
14

Insulin resistance: Review of the underlying molecular mechanisms.
Habib Yaribeygi, Farin Rashid Farrokhi, Alexandra E Butler, Amirhossein Sahebkar. J Cell Physiol 2019
105
14

Recent Advances in Protein Tyrosine Phosphatase 1B Targeted Drug Discovery for Type II Diabetes and Obesity.
Neelesh Maheshwari, Chandrabose Karthikeyan, Piyush Trivedi, N S Hari Narayana Moorthy. Curr Drug Targets 2018
26
14

Comparative pharmacokinetics of three SGLT-2 inhibitors sergliflozin, remogliflozin and ertugliflozin: an overview.
Ranjeet Prasad Dash, R Jayachandra Babu, Nuggehally R Srinivas. Xenobiotica 2017
10
14

Overview of Ertugliflozin.
Vivianne K Nguyen, John R White. Clin Diabetes 2019
2
50


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.